Shionogi buys out sleep science venture for $100 million

Recent headlines claiming that Japanese pharmaceutical firm Shionogi bought out a sleep science venture for $100 million may be misleading.

orgShionogi

In reality, Shionogi and the Massachusetts-based biotech Apnimed have formed a deep strategic partnership.

orgShionogi

orgApnimed

In November 2023, they launched a 50-50 joint venture called Shionogi-Apnimed Sleep Science (SASS).

orgShionogi-Apnimed Sleep Science

orgSASS

This initiative focuses on developing new oral treatments for Obstructive Sleep Apnea (OSA).

conceptObstructive Sleep Apnea

conceptOSA

Unlike a total company acquisition, this collaboration combines Shionogi’s drug discovery expertise with Apnimed’s clinical research.

orgShionogi

conceptdrug discovery

orgApnimed

By 2025, the partnership expanded to include the drug sulthiame in their development pipeline.

techsulthiame

Financial reports mentioning a $100 million figure often confuse this deal with unrelated funding rounds for 'sleep-fitness' technology firms like Eight Sleep.

conceptsleep-fitness

orgEight Sleep

Through SASS, the two companies aim to provide non-surgical, medication-based alternatives for patients.

orgSASS

🎉

End of article

You read 8 focus sentences.

Challenge Mode

Comprehension Questions

What is the primary goal of the Shionogi-Apnimed Sleep Science (SASS) joint venture?

To develop novel oral pharmacological treatments for sleep apnea.

To fully acquire Apnimed’s late-stage lead drug programs.

To manufacture sleep-tracking fitness technology devices.

Reveal Answer

✓

Correct Choice

To develop novel oral pharmacological treatments for sleep apnea.

How should the relationship between Shionogi and Apnimed be described?

As a hostile takeover initiated by Shionogi.

As a strategic 50-50 joint venture.

As an unrelated investment in the Eight Sleep firm.

Reveal Answer

✓

Correct Choice

As a strategic 50-50 joint venture.

Why might some people be confused about the $100 million figure?

Because a separate company called Eight Sleep held a $100 million funding round.

Because SASS was sold to a technology company for that price.

Because Shionogi paid exactly $100 million to acquire Apnimed.

Reveal Answer

✓

Correct Choice

Because a separate company called Eight Sleep held a $100 million funding round.

What was the significance of the 2025 expansion of the partnership?

It added the antiepileptic drug sulthiame to the SASS development program.

It marked the total dissolution of the joint venture.

It shifted the focus to surgical sleep treatments.

Reveal Answer

✓

Correct Choice

It added the antiepileptic drug sulthiame to the SASS development program.

Which of the following is true regarding Apnimed's lead drug programs?

They were not included in the SASS joint venture.

They were sold to Shionogi for $150 million.

They were the primary focus of the 2023 joint venture.

Reveal Answer

✓

Correct Choice

They were not included in the SASS joint venture.

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App Store Google Play